Transcriptional targeting for ovarian cancer gene therapy

Gynecologic Oncology

Volumn 82, Issue 2, 2001, Pages 229-237

  Casado, E ^a,b   Nettelbeck, D M ^a,b   Gomez Navarro, J ^a,b   Hemminki, A ^a,b   Gonzalez Baron, M ^c   Siegal, G P ^b,d   Barnes, M N ^e   Alvarez, R D ^b,e   Curiel, D T ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Gene therapy; Ovarian cancer; Transcriptional targeting; Tumor specific promoters

Indexed keywords

ACTIN BINDING PROTEIN; ALPHA FETOPROTEIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOSINE DEAMINASE; DIPHTHERIA TOXIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; FLUCYTOSINE; GANCICLOVIR; LIPOSOME; MATRILYSIN; MIDKINE; MUCIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; THYMIDINE KINASE; VASCULOTROPIN;

CYTOMEGALOVIRUS; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; NONHUMAN; OVARY CANCER; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SUICIDE GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

EID: 0034904338     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6305     Document Type: Review

References (112)

1. The epidemiology of ovarian cancer
2. Ovarian cancer
3. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability
4. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma
5. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells
6. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver
7. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer
8. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir
9. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine
10. Gene therapy for cancer
11. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy
12. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: A specific gene therapy strategy
13. Development of clinical trial of E1A gene therapy targeting HER-2/neu- overexpressing breast and ovarian cancer
14. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer
15. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer
16. Adenoviral-mediated suicide gene therapy for ovarian cancer
17. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial
18. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer
19. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu
20. The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study
21. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial
22. Methods of gene delivery
23. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
24. Genetic targeting of adenoviral vectors
25. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a cox-sackievirus and adenovirus receptor-independent cell entry mechanism
26. Gene therapy: Promises, problems and prospects
27. Gene therapy: Designer promoters for turnout targeting
28. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting
29. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
30. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
31. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines
32. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter
33. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies
34. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors
35. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
36. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression
37. In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines
38. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells
39. Strategy for achieving selective killing of carcinomas
40. A recombinant adenoviral vector with selective transgene expression in ovarian cancer cells
41. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme
42. Expression of the DF3-P epitope in human ovarian carcinomas
43. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene
44. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors
45. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
46. Activation of the leukocyte plastin gene occurs in most human cancer cells
47. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
48. Cytotoxicity of cytosine deaminase (CD) adenoviral vectors (AV) with a promoter (L-plastin) for epithelial cancer cells (Meeting abstract)
49. Molecular aspects of ovarian cancer. Is gene therapy the solution?
50. Molecular pathology of ovarian carcinomas
51. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?
52. Gene therapy: Ovarian carcinoma as the paradigm
53. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors
54. Telomerase activity in ovarian tumors
55. Expression of midkine and pleiotropin in ovarian tumors
56. Analysis of human transcriptomes
57. Cancer de ovario
58. Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line
59. More than 15 years of CA 125: What is known about the antigen, its structure and its function
60. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125
61. Radiation-induced CA 125 production by mesothelial cells
62. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival
63. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth
64. Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy
65. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray
66. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers
67. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line
68. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer
69. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment
70. Increased cell-surface urokinase in advanced ovarian cancer
71. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells
72. Expression of cyclooxygenase-2 in human gastric carcinoma
73. Clinical evaluations of a new ovarian cancer marker, COX-1
74. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer
75. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery
76. A new biological strategy for high productivity of recombinant proteins in animal cells by the use of hypoxia-response enhancer
77. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: A specific gene therapy strategy
78. Development of a retroviral vector for inducible expression of transforming growth factor beta 1
79. Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors
80. Replicative adenoviruses for cancer therapy
81. Use of L-plastin promoter to generate conditionally replication competent adenoviral vectors which are directly lytic for ovarian cancer cells
82. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas
83. Growth factor receptor tyrosine kinases
84. Gene therapy for cancer using tumour-specific prodrug activation
85. Insulation of a conditionally expressed transgene in an adenoviral vector
86. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: Immunohistochemical findings and prognostic value
87. Complexity of signal transduction mediated by ErbB2: Clues to the potential of receptor-targeted cancer therapy
88. Amplification of the c-myc gene and the elevation of its transcripts in human ovarian tumor lines
89. Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer
90. The relevance of c-myc to the physiology of the human ovary
91. Inducible regulatory elements in the human cyclin D1 promoter
92. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors
93. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors
94. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors
95. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
96. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors
97. Telomerase activity in benign and malignant epithelial ovarian tumors
98. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors
99. Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: Correlation with sensitivity to DNA damaging agents
100. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas
101. A novel telomerase-specific gene therapy: Gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter
102. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice
103. Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: Potential uses of X-ray-responsive elements for gene therapy
104. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma
105. Inhibin as a marker for granulosa-cell tumors
106. Inhibin as a marker for granulosa cell tumor
107. Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumours of the ovary
108. Inhibin as a marker for ovarian cancer
109. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma
110. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
111. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary
112. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels